The current position of β-blockers in hypertension: guidelines and clinical practice

• Published in: Current medical research and opinion 2024, Vol.40 (sup1), p.25-32
• Main Authors: Mahfoud, Felix, Wang, Jiguang, Ray, Saumitra
• Format: Article
• Language: English
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Antihypertensive Agents - therapeutic use; Calcium Channel Blockers - therapeutic use; Heart Failure - drug therapy; Humans; Hypertension - drug therapy; Hypotension - drug therapy
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1080/03007995.2024.2318003

The benefits of improved clinical outcomes through blood pressure (BP) reduction have been proven in multiple clinical trials and meta-analyses. The new (2023) guideline from the European Society of Hypertension (ESH) includes β-blockers within five main classes of antihypertensive agents suitable for initiation of antihypertensive pharmacotherapy and for combination with other antihypertensive agents. This is in contrast to the 2018 edition of ESH guidelines that recommended β-blockers for use primarily in patients with compelling indications such as cardiovascular comorbidities, e.g. coronary heart disease, heart failure. This change was based on the fact that the magnitude of BP reduction is the most important factor for adverse cardiovascular outcomes, over and above the precise manner in which reduced BP is achieved. The ESH guideline also supports the use of β-blockers for patients with resting heart rate (>80 bpm); high resting heart rate is a sign of sympathetic overactivity, an important driver of adverse cardiac remodelling in the setting of hypertension and heart failure. Hypertension management guidelines support for the use of combination therapies for almost all patients with hypertension, ideally within a single-pill combination to optimise adherence to therapy. Where a β-blocker is prescribed, the inclusion of a dihydropyridine calcium channel blocker within a combination regimen is rational. These agents together reduce both peripheral and central BP, which epidemiological studies have shown is important for reducing the burden of premature morbidity and mortality associated with uncontrolled hypertension, especially strokes.